EGFR and cancer: In common cancers such as NSCLC, publications have reported on an overall concordance of 81% when focused on one specific gene alteration such as EGFR, whereas the concordance rate was 53% when the concordance analysis included all alterations that were potentially detectable by both tests (i.e., included in both gene panels) as in our study (1, 17).